SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-098883
Filing Date
2022-04-07
Accepted
2022-04-07 16:11:09
Documents
17
Period of Report
2022-04-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d346885d8k.htm   iXBRL 8-K 31488
2 EX-1.1 d346885dex11.htm EX-1.1 212167
3 EX-5.1 d346885dex51.htm EX-5.1 9422
7 GRAPHIC g346885g0407080054272.jpg GRAPHIC 1584
8 GRAPHIC g346885g0407080054772.jpg GRAPHIC 1817
9 GRAPHIC g346885g0407080055132.jpg GRAPHIC 5840
  Complete submission text file 0001193125-22-098883.txt   449039

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA akba-20220407.xsd EX-101.SCH 2841
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20220407_lab.xml EX-101.LAB 17235
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20220407_pre.xml EX-101.PRE 10802
11 EXTRACTED XBRL INSTANCE DOCUMENT d346885d8k_htm.xml XML 3230
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 22813980
SIC: 2834 Pharmaceutical Preparations